Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2003
03/18/2003US6534487 Methods for suppressing appetite and enhancing exercise and recovery
03/18/2003US6534483 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods
03/18/2003US6534479 Recombinant alpha-fetoprotein hybrid cytotoxins for treating and diagnosing cancers
03/18/2003US6534110 Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids
03/18/2003US6534093 Immediate release eplerenone compositions
03/18/2003US6534092 Method for preparing microparticles having a selected polymer molecular weight
03/18/2003US6534091 Microcapsules
03/18/2003US6534088 Fibrate-statin combinations with reduced fed-fasted effects
03/18/2003US6534087 Process for preparing a pharmaceutical composition
03/18/2003US6534085 Phytochemicals for promoting weight loss
03/18/2003US6534081 Administration of microparticles in a form suitable for injection and containing active agents suitable for treating or diagonising a disease or painful condition in joints in a patient in need, safe and effective procedure; sustained
03/18/2003US6534070 Composition with azelaic acid
03/18/2003US6534069 Disinfectant, antimicrobial hand lotion comprising thickener, emulsifier, lower alcohol and water
03/18/2003US6534065 Influenza vaccine composition with chitosan adjuvant
03/18/2003US6534061 Isolated DNA98853 and DNA101848 polypeptides
03/18/2003US6534054 Probiotic/therapeutic uses of nonpathogenic probiobiotic microorganisms; manufacturing the formulation from the plant derived material
03/18/2003US6534053 Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications
03/18/2003US6534051 Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
03/18/2003US6534048 Aqueous gel in unit dose form for topical delivery
03/18/2003US6534018 Precisely controlled in line metering system for mixing suspensions, emulsions, ointments and creams
03/18/2003CA2403495A1 Physically stable sprayable gel composition
03/18/2003CA2299231C Compressed nitroglycerin tablet and its method of manufacture
03/18/2003CA2231223C Novel composition containing an acid-labile omeprazole and process for its preparation
03/18/2003CA2223732C Preservative system and its use in a cosmetic or pharmaceutical composition
03/18/2003CA2216417C Controlled release of miotic and mydriatic drugs in the anterior chamber
03/18/2003CA2210321C Pharmaceutical compositions in the form of slow release tablets based on high molecular weight polysaccharide granules
03/18/2003CA2141334C Cationic lipids
03/18/2003CA2107107C Improvements in or relating to contrast agents
03/18/2003CA2059432C Surface modified drug nanoparticles
03/17/2003WO2002022833A1 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
03/17/2003CA2422759A1 Fusion protein from antibody cytokine-cytokine inhibitor (selectokine) for use as target-specific prodrug
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020876A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
03/13/2003WO2003020771A1 Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use
03/13/2003WO2003020763A2 Soluble t cell receptor
03/13/2003WO2003020751A2 Homing peptides
03/13/2003WO2003020746A1 Modified transferrin fusion proteins
03/13/2003WO2003020325A2 Methods for sterilizing preparations containing albumin
03/13/2003WO2003020324A2 Methods for sterilizing preparations of digestive enzymes
03/13/2003WO2003020323A1 Light-stabilized $i(in vivo) stain composition and method of manufacture
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020319A1 A w/o-emulsion carrier composition
03/13/2003WO2003020318A1 A topical w/o-emulsion composition
03/13/2003WO2003020316A1 Materials sustainedly releasing drug in vivo
03/13/2003WO2003020299A1 L-methionine as a stabilizer for nesp/epo in hsa-free formulations
03/13/2003WO2003020291A1 Increased solubility flavanolignan preparations
03/13/2003WO2003020265A2 Compositions comprising pectin and ascorbic acid
03/13/2003WO2003020262A2 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
03/13/2003WO2003020261A1 Pharmaceutical composition comprising lumiracoxib
03/13/2003WO2003020253A2 Pharmaceutical compositions for the treatment of asthma
03/13/2003WO2003020250A1 Plaster for the treatment of dysfunctions and disorders of nail growth
03/13/2003WO2003020249A1 Plaster for the treatment of dysfunctions and disorders of nails
03/13/2003WO2003020248A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
03/13/2003WO2003020247A1 Process for coating solid particles
03/13/2003WO2003020246A1 Injection molding process for the preparation of an oral delivery device for a pharmaceutically active agent
03/13/2003WO2003020245A1 Residual solvent extraction method and microparticles produced thereby
03/13/2003WO2003020244A1 Process for dispersing a fluid in solid particles
03/13/2003WO2003020242A1 Sustained release preparations
03/13/2003WO2003020241A2 Functional powders for oral delivery
03/13/2003WO2003020235A2 Stabilisation of oxidation-sensitive and uv-sensitive active ingredients
03/13/2003WO2003020227A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia
03/13/2003WO2003020219A2 Aerosolized decongestants for the treatment of sinusitis
03/13/2003WO2003020212A2 Treatment for central nervous system disorders
03/13/2003WO2003020210A2 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
03/13/2003WO2003020207A1 Aqueous air foam
03/13/2003WO2003020203A2 Hydrogenated castor oil dispersed in a lipid for pharmaceutically elegant topical ointments
03/13/2003WO2003020200A2 A novel pharmaceutical compound and methods of making and using same
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020040A1 Oral vaccines
03/13/2003WO2003020037A1 Multivesicular emulsion topical delivery systems
03/13/2003WO2003000225A3 Pharmaceutical formulation having a masked taste and method for the production thereof
03/13/2003WO2003000174A3 Compositions and methods for intracellular delivery
03/13/2003WO2002094774A3 Oxcarbazepine dosage forms
03/13/2003WO2002083840A3 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
03/13/2003WO2002083097A3 Drug delivery system for hydrophobic drugs
03/13/2003WO2002080850A3 Bulking agents as satiety agents
03/13/2003WO2002078622A3 Targeted oxidative therapeutic formulation
03/13/2003WO2002075275A3 Polyclonal populations of bispecific molecules and methods of production and uses thereof
03/13/2003WO2002072033A3 Chronotherapeutic dosage forms containing glucocorticosteroid
03/13/2003WO2002069939A3 Taste masked pharmaceutical compositions
03/13/2003WO2002067902A3 Modulation of release from dry powder formulations
03/13/2003WO2002066469A3 Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
03/13/2003WO2002065986A9 Transporters comprising spaced arginine moieties
03/13/2003WO2002062832A3 Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
03/13/2003WO2002060396A3 Hair follicle neogenesis by injection of follicle progenitor cells
03/13/2003WO2002058739A3 Orally ingestible baked radiopaque product for testing for dysphagia
03/13/2003WO2002047717A3 Targeted enzyme prodrug therapy
03/13/2003WO2002045684A3 Rapidly dispersing pharmaceutical composition comprising effervescent agents
03/13/2003WO2002041878A3 Titratable dosage transdermal delivery system
03/13/2003WO2002034293A3 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
03/13/2003WO2002030465A3 Compositions that inhibit proliferation of cancer cells
03/13/2003WO2002030460A3 Therapeutic antibodies
03/13/2003WO2002030398A3 Delayed release pharmaceutical formulations
03/13/2003WO2002030391A3 Method for determining the release of a peptide from a sustained release polylactide formulation
03/13/2003WO2002026822A3 Pumpcn compositions and uses thereof
03/13/2003WO2002022154A3 Pharmaceutical compositions for sustained drug delivery
03/13/2003WO2001097848A3 Vitronectin receptor antagonist pharmaceuticals
03/13/2003WO2001036515A3 Polymeric compositions and a method of making the same
03/13/2003US20030050447 Polypeptide for use in the generation of vaccine against diphtheria toxin
03/13/2003US20030050344 Thyroid hormones or their salts in capsule or in swallowable uniform soft-gel gelatin matrices for treatment of hypothyroidism
1 ... 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 ... 1712